ArticleClinical case reports2025
Apical Surgery of a Maxillary Left Central Tooth Using NeoPutty After Retreatment Failure: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative evaluation of NeoPUTTY and mineral trioxide aggregate for full pulpotomy in mature permanent molars with irreversible pulpitis: a randomized clinical study.Biomaterial investigations in dentistry · 2026Article
- Apical Surgery of a Maxillary Left Central Tooth Using NeoPutty After Retreatment Failure: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports a successful apical surgery performed on a maxillary central incisor in a middle-aged man with a persistent infection following non-surgical endodontic retreatment. The infection involved both labial and palatal bone perforations. NeoPutty, a new bioactive bioceramic putty available in a premixed format, was used in this case. Its primary components are tricalcium and dicalcium silicate. NeoPutty has demonstrated antibacterial properties and biocompatibility, and has been successfully used in primary molar pulpotomy and indirect pulp therapy. In the present study, it was utilized for root-end filling for the first time, contributing to a favorable surgical outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.